1e
19
1
49
2
2
18
1b
1d
18
38
57
1d
2 29
1d
25
James F. Markmann, MD, PhD
78
57
William Maul Measey Professor in Surgical Research
28
86
3
5e
Attending Surgeon, Hospital of the University of Pennsylvania, Philadelphia, PA
7b
Courtesy Surgeon, Penn Presbyterian Medical Center, Philadelphia, PA
70
Courtesy Surgeon, Pennsylvania Hospital, Philadelphia, PA
ad
Vice President for Transplantation Services, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
11
Department: Surgery
4
1
b
1d
46
Contact information
4c
4
3
3
3
2
29
4
b
1f
4c
Division of Transplant Surgery
32 Hospital of the University of Pennsylvania
48 3400 Spruce Street, 2 Dulles Building
Philadelphia, PA 19104
26
32 Hospital of the University of Pennsylvania
48 3400 Spruce Street, 2 Dulles Building
Philadelphia, PA 19104
2e
Office: 215-662-4083
32 Fax: 215-614-1795
24
f
32 Fax: 215-614-1795
24
13
Education:
21 7 BA c
3d LaSalle University, Philadelphia, PA, 1983.
21 7 MD c
58 University of Pennsylvania School of Medicine, Philadelphia, PA, 1989.
21 8 PhD 17 (Immunology) c
58 University of Pennsylvania School of Medicine, Philadelphia, PA, 1989.
c
3
3
3
3
8a
Permanent link21 7 BA c
3d LaSalle University, Philadelphia, PA, 1983.
21 7 MD c
58 University of Pennsylvania School of Medicine, Philadelphia, PA, 1989.
21 8 PhD 17 (Immunology) c
58 University of Pennsylvania School of Medicine, Philadelphia, PA, 1989.
c
2 29
21
1e
1d
24
5e
8
338 Dr. Markmann's lab works on basic Transplantation Immunology and has three general areas of interest: First, we are working on gene based strategies to improve graft survival. We have constructed viral vectors encoding immunosuppressive or immunomodulatory moelcules to impact the host response to allografts. Second, we have focused on characterization of a particular population of immunoregulatory T cells that are know to be critical for self-tolerance as a means to induce tolerance to an allograft. Finally, we have recently begun clinical trials of human isolated islet transplantation. A number of projects in the lab center on ways to improve the efficiency of islet function or ways to improve islet transplant success by inducing replication of islet cells or differentiation of beta cells form stem cells.
65
1a 29
27
Description of Research Expertise
229 James Markmann, M.D. is a board certified general surgeon with extensive specialty training in all areas of abdominal organ transplantation. He has a highly active clinical practice in liver, kidney and simultaneous kidney-pancreas transplantation. His special interests include: treatment of hepatobiliary malignancy, living-related and split liver transplantation, transplantation for Type I diabetes (pancreas and islet transplantation), and minimally invasive approaches to transplant surgery such as laparoscopic donor nephrectomy.8
338 Dr. Markmann's lab works on basic Transplantation Immunology and has three general areas of interest: First, we are working on gene based strategies to improve graft survival. We have constructed viral vectors encoding immunosuppressive or immunomodulatory moelcules to impact the host response to allografts. Second, we have focused on characterization of a particular population of immunoregulatory T cells that are know to be critical for self-tolerance as a means to induce tolerance to an allograft. Finally, we have recently begun clinical trials of human isolated islet transplantation. A number of projects in the lab center on ways to improve the efficiency of islet function or ways to improve islet transplant success by inducing replication of islet cells or differentiation of beta cells form stem cells.
65
Description of Clinical Expertise
d7 My clinical activities focus on liver, kidney and pancreas transplantation and care of transplant patients. I also perform pancreatic auto and allo transplants and stem cell derived islet transplants1a 29
23
74 Lee MK 4th, Moore DJ, Jarrett BP, Lian MM, Deng S, Huang X, Markmann JW, 104 Chiaccio M, Barker CF, Caton AJ, Markmann JF: Promotion of allograft survival by CD4+CD25+ regulatory T cells: evidence for in vivo inhibition of effector cell proliferation. Journal of Immunology 172(11): 6539-6544, June 1 2004.
118 Kobinger GP, Deng S, Louboutin JP, Vatamaniuk M, Matschinsky F, Markmann JF, Raper SE, Wilson JM: Transduction of human islets with pseudotyped lentiviral vectors. Human Gene Therapy 15(2): 211-9, Feb. 2004.
77 Abt PL, Desai NM, Crawford MD, Forman LM, Markmann JW, Olthoff KM, Markmann 96 JF: Survival following liver transplantation from non-heart-beating donors. Annals of Surgery 239(1): 87-92, Jan. 2004.
76 Wu Z, Bensinger SJ, Zhang J, Chen C, Yuan X, Huang X, Markmann JF, Kassaee 7e A, Rosengard BR, Hancock WW, Sayegh MH, Turka LA: Homeostatic proliferation is a barrier to transplantation tolerance 5b Nature Medicine 10(1): 87-92, Jan. 2004 Notes: Epub Nov. 30, 2003.
e1 Lee MK 4th, Moore DJ, Markmann JF: Regulatory CD4+CD25+T cells in prevention of allograft rejection. Frontiers in Bioscience 8: s968-s981, Sept. 1 2003.
158 Cao X, Gao Z, Robert CE, Greene S, Xu G, Xu W, Bell E, Campbell D, Zhu Y, Young R, Trucco M, Markmann JF, Naji A, Wolf BA: Pancreatic-derived factor (FAM3B), a novel islet cytokine, induces apoptosis of insulin-secreting beta-cells. Diabetes 52(9): 2296-2303, Sept. 2003.
12b Htaik TT, Santaniello NA, Markmann JF, Shaked A, Clark TW: Treatment of obstructive nephroureteral clot with a rheolytic mechanical thrombectomy device. Journal of Vascular & Interventional Radiology 14(7): 933-936, July 2003.
145 Markmann JF, Rosen M, Siegelman ES, Soulen MC, Deng S, Barker CF, Naji A: Magnetic resonance-defined periportal steatosis following intraportal islet transplantation: A functional footprint of islet graft survival? Diabetes 52(7): 1591-1594, July 2003.
187 Markmann JF, Deng S, Huang X, Desai NM, Velidedeoglu EH, Lui C, Frank A, Markmann E, Palanjian M, Brayman K, Wolf B, Bell E, Vitamaniuk M, Doliba N, Matschinsky F, Barker CF, Naji A: Insulin independence following isolated islet transplantation and single islet infusions. Annals of Surgery 237(6): 741-750, June 2003.
2c
7
1d
1f
Selected Publications
75 Velidedeoglu E, Mange KC, Frank A, Abt P, Desai NM, Markmann JW, Reddy R, c5 Markmann JF: Factors differentially correlated with the outcome of liver transplantation in HCV+ and HCV- recipients. Transplantation 77(12): 1834-1842, June 27 2004.74 Lee MK 4th, Moore DJ, Jarrett BP, Lian MM, Deng S, Huang X, Markmann JW, 104 Chiaccio M, Barker CF, Caton AJ, Markmann JF: Promotion of allograft survival by CD4+CD25+ regulatory T cells: evidence for in vivo inhibition of effector cell proliferation. Journal of Immunology 172(11): 6539-6544, June 1 2004.
118 Kobinger GP, Deng S, Louboutin JP, Vatamaniuk M, Matschinsky F, Markmann JF, Raper SE, Wilson JM: Transduction of human islets with pseudotyped lentiviral vectors. Human Gene Therapy 15(2): 211-9, Feb. 2004.
77 Abt PL, Desai NM, Crawford MD, Forman LM, Markmann JW, Olthoff KM, Markmann 96 JF: Survival following liver transplantation from non-heart-beating donors. Annals of Surgery 239(1): 87-92, Jan. 2004.
76 Wu Z, Bensinger SJ, Zhang J, Chen C, Yuan X, Huang X, Markmann JF, Kassaee 7e A, Rosengard BR, Hancock WW, Sayegh MH, Turka LA: Homeostatic proliferation is a barrier to transplantation tolerance 5b Nature Medicine 10(1): 87-92, Jan. 2004 Notes: Epub Nov. 30, 2003.
e1 Lee MK 4th, Moore DJ, Markmann JF: Regulatory CD4+CD25+T cells in prevention of allograft rejection. Frontiers in Bioscience 8: s968-s981, Sept. 1 2003.
158 Cao X, Gao Z, Robert CE, Greene S, Xu G, Xu W, Bell E, Campbell D, Zhu Y, Young R, Trucco M, Markmann JF, Naji A, Wolf BA: Pancreatic-derived factor (FAM3B), a novel islet cytokine, induces apoptosis of insulin-secreting beta-cells. Diabetes 52(9): 2296-2303, Sept. 2003.
12b Htaik TT, Santaniello NA, Markmann JF, Shaked A, Clark TW: Treatment of obstructive nephroureteral clot with a rheolytic mechanical thrombectomy device. Journal of Vascular & Interventional Radiology 14(7): 933-936, July 2003.
145 Markmann JF, Rosen M, Siegelman ES, Soulen MC, Deng S, Barker CF, Naji A: Magnetic resonance-defined periportal steatosis following intraportal islet transplantation: A functional footprint of islet graft survival? Diabetes 52(7): 1591-1594, July 2003.
187 Markmann JF, Deng S, Huang X, Desai NM, Velidedeoglu EH, Lui C, Frank A, Markmann E, Palanjian M, Brayman K, Wolf B, Bell E, Vitamaniuk M, Doliba N, Matschinsky F, Barker CF, Naji A: Insulin independence following isolated islet transplantation and single islet infusions. Annals of Surgery 237(6): 741-750, June 2003.
2c